Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Melisi

Showing results (51-60 of 128) with videos related to

Pageof 13
Sort By:
World Journal of Gastroenterology|May 7, 2015
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Vanja Vaccaro, Isabella Sperduti, Sabrina Vari, et al.
Oncotarget|November 1, 2014
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesisCarmine Carbone, Geny Piro, Matteo Fassan, et al.
Frontiers in Oncology|March 29, 2021
Targeting KRAS: The Elephant in the Room of Epithelial CancersValeria Merz, Marina Gaule, Camilla Zecchetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastomaVincenzo Damiano, Davide Melisi, Cataldo Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapyFortunato Ciardiello, Roberto Bianco, Roberta Caputo, et al.
Anti-Cancer Drugs|October 17, 2015
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatmentCarmine Carbone, Anna Tamburrino, Geny Piro, et al.
Molecular Cancer Therapeutics|August 10, 2004
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft modelDavid Raben, Cataldo Bianco, Vincenzo Damiano, et al.
Oncogene|April 13, 2026
EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophagesSilvia Pietrobono, Veronica De Vita, Domenico Mangiameli, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimusA Rose Brannon, Melissa Frizziero, David Chen, et al.
NPJ Precision Oncology|October 31, 2024
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophagesSilvia Pietrobono, Monica Bertolini, Veronica De Vita, et al.
Pageof 13

Showing results (51-60 of 128) with videos related to

Sort By:
Pageof 13
World Journal of Gastroenterology|May 7, 2015
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Vanja Vaccaro, Isabella Sperduti, Sabrina Vari, et al.
Oncotarget|November 1, 2014
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesisCarmine Carbone, Geny Piro, Matteo Fassan, et al.
Frontiers in Oncology|March 29, 2021
Targeting KRAS: The Elephant in the Room of Epithelial CancersValeria Merz, Marina Gaule, Camilla Zecchetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastomaVincenzo Damiano, Davide Melisi, Cataldo Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapyFortunato Ciardiello, Roberto Bianco, Roberta Caputo, et al.
Anti-Cancer Drugs|October 17, 2015
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatmentCarmine Carbone, Anna Tamburrino, Geny Piro, et al.
Molecular Cancer Therapeutics|August 10, 2004
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft modelDavid Raben, Cataldo Bianco, Vincenzo Damiano, et al.
Oncogene|April 13, 2026
EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophagesSilvia Pietrobono, Veronica De Vita, Domenico Mangiameli, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimusA Rose Brannon, Melissa Frizziero, David Chen, et al.
NPJ Precision Oncology|October 31, 2024
CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophagesSilvia Pietrobono, Monica Bertolini, Veronica De Vita, et al.
Pageof 13